ERBB2 and ovarian cancer: Specifically, one pre-clinical study was aimed at understanding why saracatinib did not improve the outcomes of women with platinum-resistant ovarian cancer, and their results suggest that the activation of the MAPK signalling pathway through the reduction in NF1 (neurofibromin) or overexpression of HER2/insulin receptor leads to resistance to AZD0530 in ovarian cancer cell lines.